FutuRx

2022年1月20日

impact由美國Kalthera公司和以色列FutuRX生物技術孵化器公司合並而成。以色列-美國公司impact Bio宣布完成1.11億美元的融資，該公司正在開發下一代癌細胞療法。impact Bio由以色列公司impact和美國公司Kalthera合並而成，前者成立於FutuRX生物技術孵化器，後者成立於加州的生物技術領域。由Erez Chimovits領導的FutuRX是以色列創新局技術孵化器網絡的一部分，該網絡致力於藥物開發。孵化器加盟商是由OrbiMed風險投資基金、日本製藥巨頭武田和強生公司組成的財團。OrbiMed參與了今天的融資，由venBio Partners、Foresite Capital和Decheng Capital、Surveyor Capital以及現有投資者Novartis Venture Fund、RM Global Partners (RMGP)和Bukwang Pharmaceutical共同領投。到目前為止，奇莫維茨一直擔任董事長。impact基於邏輯門的CAR - T平台解決了治療癌症的關鍵生物學挑戰。impact Bio的技術專門用於解決抗原逃逸、“靶外腫瘤”毒性和免疫抑製腫瘤微環境問題。impact Bio任命Sumant Ramachandra為總裁兼首席執行官。 He said, "The US company brings with it two products, one of which is already in human clinic trials and one in advanced clinical trials." Both products are in the field of Tandem CAR, He added, "But the Israeli product is even more interesting. It is based on research by Prof. Gidi Gross from the Migal Institute. Gross was one of the researchers who wrote the article on which Kite pharma was based, and which is considered one of the pioneers in the CAR sector, and was which was acquired by Gilead for $11.9 billion." The company has two research centers in California and Israel and with the money raised it will build new research laboratories and a small production plant for therapies for clinical trials. The company has 23 employees and aims to increase the number to 65 by the end of the year. Published by Globes, Israel business news - en.globes.co.il - on January 20, 2022. © Copyright of Globes Publisher Itonut (1983) Ltd., 2022.